HR+ BREAST CANCER
Clinical trials for HR+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+ BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted drug SC-101 takes aim at Hard-to-Treat breast cancers
Disease control Not yet recruitingThis study tests a new drug called SC-101 in people with advanced breast cancer that has a specific gene change (NECTIN4). The goal is to see if the drug can shrink tumors and how safe it is. About 120 adults aged 18-75 with triple-negative or HR+ breast cancer will take part.
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New drug combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this approach can eliminate cancer more effectively than standard chemo, while reducing…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
CBD oil tested for hormone therapy joint pain in breast cancer patients
Symptom relief Not yet recruitingThis study tests whether a CBD oil solution can reduce joint pain caused by hormone therapy (aromatase inhibitors) in people with early-stage, hormone-receptor-positive breast cancer. About 130 participants will receive either CBD or a placebo, then switch treatments to compare e…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated May 22, 2026 14:03 UTC